Table 4.
Reclassification and discrimination statistics (95% CIs) for the primary endpoint
| Clinical risk model | C-statistic (95% CI) | NRI (95% CI) | P-value | IDI (95% CI) | P-value |
|---|---|---|---|---|---|
| Copeptin |
0.636 (0.564 – 0.708) |
||||
| MR-proANP |
0.667 (0.597 – 0.738) |
||||
| Hs-cTnI |
0.697 (0.626 – 0.768) |
||||
| MR-proANP / hs-cTnI |
0.695 (0.623 – 0.768) |
||||
| Copeptin / hs-cTnI |
0.718 (0.646 – 0.789) |
||||
| Baseline model |
0.802 (0.735 – 0.870) |
||||
| Baseline model + Copeptin |
0.816 (0.747 – 0.886) |
0.545 (0.259 – 0.830) |
< 0.001 |
0.026 (0.004 – 0.048) |
0.019 |
| Baseline model + MR-proANP |
0.808 (0.739 – 0.877) |
0.377 (0.076 – 0.678) |
0.014 |
0.027 (0.005 – 0.049) |
0.015 |
| Baseline model + hs-cTnI |
0.815 (0.751 – 0.879) |
0.634 (0.3491 – 0.918) |
< 0.001 |
0.025 (0.001 – 0.050) |
0.046 |
| Baseline model + Copeptin / hs-cTnI |
0.829 (0.765 – 0.893) |
0.702 (0.412 – 0.991) |
< 0.001 |
0.072 (0.032 – 0.112) |
< 0.001 |
| Baseline model + MR-proANP / hs-cTnI |
0.810 (0.743 – 0.877) |
0.499 (0.205 – 0.793) |
< 0.001 |
0.027 (0.003 – 0.051) |
0.03 |
| 4C deterioration model |
0.799 (0.731 – 0.867) |
||||
| 4C deterioration model + Copeptin |
0.804 (0.736 – 0.871) |
0.545 (0.259 – 0.830) |
< 0.001 |
0.014 (-0.004 – 0.031) |
0.126 |
| 4C deterioration model + MR-proANP |
0.806 (0.737 – 0.876) |
0.670 (0.389 – 0.950) |
< 0.001 |
0.024 (0.004 – 0.045) |
0.021 |
| 4C deterioration model + hs-cTnI |
0.818 (0.753 – 0.884) |
0.787 (0.504 – 1.070) |
< 0.001 |
0.037 (0.009 – 0.006) |
0.009 |
| 4C deterioration model + Copeptin / hs-cTnI |
0.837 (0.774 – 0.900) |
0.871 (0.587 – 1.155) |
< 0.001 |
0.072 (0.030 – 0.114) |
< 0.001 |
| 4C deterioration model + MR-proANP / hs-cTnI |
0.816 (0.748 – 0.883) |
0.781 (0.493—1.069) |
< 0.001 |
0.039 (0.011 – 0.067) |
< 0.001 |
The base model included age, gender, arterial hypertension, history of cardiovascular disease, chronic kidney disease, dyspnea, heart rate, respiratory rate, mean blood pressure and body temperature